|
KMID : 1142020210560000001
|
|
Blood Research
2021 Volume.56 No. 0 p.1 ~ p.4
|
|
|
Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
|
|
Yi Jun-Ho
|
|
|
Abstract
|
|
|
|
Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.
|
|
|
KEYWORD
|
|
|
B-cell lymphoma, CD19, CD22, CD79b
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|